David Mussafer, chairman of Advent International
Advent to sell stake in manufacturer and drug developer in a deal worth over $1B — report
After almost three years of investment, private equity firm Advent International may look to sell its part in Bioduro-Sundia.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
